Search | Clinical Trials Finder

Conditions: Healthy
Interventions: K-001, K-877-ER, CSG452; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Tourette's Disorder, Insomnia
Interventions: Forehead Temperature-Regulating Therapy; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Caries
Interventions: 0 ppm F, 250 ppm F as MFP, 1100 ppm as MFP, 2800 ppm F as MFP, 1100 ppm SnF2; Drug
Lead sponsor: Procter and Gamble; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Healthy
Interventions: PF-06821497 Treatment A, PF-06821497 Treatment B, PF-06821497 Treatment C, PF-06821497 Treatment D, PF-06821497 Treatment E, PF-06821497 Treatment F; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy
Interventions: Duragesic (Fentanyl Transdermal System [TDS] Small Patches), New JNJ-35685-AAA-G016 (Fentanyl TDS -Small Patches), Aged JNJ-35685-AAA-G016 (Fentanyl TDS Small Patches), Duragesic (Fentanyl TDS Large Patches), New JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches), Aged JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Cypress, California

Conditions: Acute Pain, Headache, Musculoskeletal Pain
Interventions: Usual Care/Guideline, Opioid Justification, Provider Comparison; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 22,616 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, Tumour Response, Advanced or Metastatic Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, PIK3CA, AKT1, PTEN, ER Positive, HER2 Positive
Interventions: AZD5363; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2024
U.S. locations: 12
States / cities: Los Angeles, California • Stanford, California • West Hollywood, California + 8 more

Conditions: Smoking Behaviors
Interventions: Participants will place the pouch between their top lip and their gum for 30 minutes as per use instructions.; Drug
Lead sponsor: JT International SA; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Knoxville, Tennessee • San Antonio, Texas

Conditions: Caries
Interventions: 0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control); Drug
Lead sponsor: Domenick Zero; Other
Eligibility: 18 Years to 85 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Disease, Acute Leukemia, Multiple Myeloma
Interventions: Rituximab, Cyclosporine, Allogenic stem cell transplant (ASCT), Conditioning Chemotherapy, TMS, FLAG, EPOCH-F, Alemtuzumab; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 74 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Nausea and Vomiting, Chemotherapy-Induced
Interventions: Casopitant (GW679769) Oral Tablets, dexamethasone, ondansetron; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Cystic Fibrosis
Interventions: VX-445/TEZ/IVA, IVA, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 53
States / cities: Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 48 more

Conditions: Substance Use Disorder (SUD), Recovery
Interventions: EMA Only, EMI Only, EMA+EMI, Neither - RSAU; Other
Lead sponsor: Chestnut Health Systems; Other
Eligibility: 18 Years and older
Enrollment: 401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 3
States / cities: Chicago, Illinois • Normal, Illinois

Conditions: Angelman Syndrome
Interventions: ION582; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 0 Years to 50 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 6
States / cities: San Diego, California • Aurora, Colorado • Chicago, Illinois + 3 more

Conditions: Nocturnal Polyuria
Interventions: Baseline EpiNP survey, Bladder diary, Testing of EpiNP baseline survey, bladder diary and a qualitative interview, No other intervention; Diagnostic Test · Other
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 30 Years and older
Enrollment: 10,190 participants
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Parkinson Disease
Interventions: Spinal cord transcutaneous stimulation (scTS); Device
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2035
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Schizophrenia
Interventions: Elpipodect, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Rogers, Arkansas • Glendale, California • Long Beach, California + 3 more

Conditions: Healthy Volunteers
Interventions: Myblu flavor A_2.4, Myblu flavor B_2.4, Myblu flavor C_2.4, Myblu flavor D_2.4, Myblu flavor E_1.2, Myblu flavor F_1.2, Myblu flavor G_2.4, Myblu flavor H_2.4; Other
Lead sponsor: Fontem US LLC; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Volunteers, Healthy Volunteers, Human Volunteers, Normal Volunteers
Interventions: entinostat, Omeprazole, Famotidine; Drug · Dietary Supplement
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Tempe, Arizona • Lincoln, Nebraska

Conditions: Low-Grade Serous Ovarian Cancer
Interventions: Avutometinib, Defactinib, Letrozole; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Atlanta, Georgia • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more

Conditions: Stressor, Individual, Alcohol Impairment, Sleep Deprivation, Impairment, Cognitive
Interventions: Alcohol Administration, Sleep Deprivation, Control; Other · Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 21 Years to 60 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: SCHIZOPHRENIA 1 (Disorder), Schizoaffecitve Disorder
Interventions: Xanomeline and trospium chloride (KarXT); Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 50 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteer
Interventions: GDC-0032 Phase III Tablet, GDC-0032 Tablet, GDC-0032 Capsule; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Skin, Skin Care, Skin Cream
Interventions: Moisturizer A, F#9155-005, Moisturizer B, F#E1387-004, Regression, Non-Regression; Drug · Other · Procedure
Lead sponsor: Johnson & Johnson Consumer Inc. (J&JCI); Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Colorado Springs, Colorado

Search by objective public record fields.

Study to Demonstrate the Bioequivalence of Single Oral Administration of K-001 Relative to Single Oral Coadministration of Separate Tablets of K-877-ER and CSG452

Forehead Temperature-Regulating Therapy for Insomnia in Adults With Tourette's Disorder

Evaluation of the Fluoride Dose Response Using In Situ Caries Model

A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants.

A Study to Evaluate the Adherence of 2 Strengths of Newly Manufactured Samples and Aged Samples of a New Formulation (JNJ-35685-AAA-G016 and JNJ-35685-AAA-G021) of Fentanyl Transdermal System Compared With Duragesic Fentanyl Transdermal Patch in Healthy Participants

Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Pain in Primary Care

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Nicotine Pouch Pharmacokinetics Abuse Liability

Evaluation of the Fluoride Dose Response of a Modified In Situ Caries Model

Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System

A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy Adults

A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

Using Smartphones to Provide Recovery Support Services

HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome

A Cross-Functional, Population-Representative, Web-Based, Epidemiologic Study to Estimate the Prevalence and Burden of Nocturia Due to Nocturnal Polyuria in the US

Spinal Cord Stimulation for Parkinson's Disease Rehabilitation

Safety, Tolerability, and Pharmacokinetics Study of Elpipodect (MK-8189) in Participants With Schizophrenia and Healthy Participants (MK-8189-011)

A Study to Evaluate Nicotine Uptake and Biomarkers in Adult Smokers Using mybluTM Electronic Cigarettes

A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult Subjects

A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer

Neurobehavioral Changes Following Spaceflight Stressors

A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia

A Study to Evaluate the Effect of Particle Size, Formulation and Food on the Pharmacokinetics of GDC-0032 in Healthy Volunteers

A Controlled Clinical Study of 2 Different Moisturizers for the Relief of Dry Skin